Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
1
Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
2
Department of Hematology and Cell Bone Marrow Transplantation (CBMT), Ospedale Centrale di Bolzano, 39100 Bolzano, Italy
3
Department of General Surgery and Medical-Surgical Specialties, Haematology Section, University of Catania, 95123 Catania, Italy
4
Division of Haematology, AOU Policlinico “Vittorio Emanuele”, 95123 Catania, Italy
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(17), 4063; https://doi.org/10.3390/cancers14174063
Submission received: 7 July 2022
/
Revised: 9 August 2022
/
Accepted: 12 August 2022
/
Published: 23 August 2022
(This article belongs to the Special Issue Hodgkin Lymphoma)
Simple Summary
Pegfilgrastim, the pegylated form of filgrastim (recombinant human GCSF) is widely adopted as supportive care for preventing neutropenia or febrile neutropenia episodes during chemotherapy. Neutropenia is directly cause of potentially severe infections and indirectly cause of treatment delivery delay. No guidelines address the pegfilgrastim role in the specific setting of Hodgkin lymphoma (HL). Since HL is a young-adult disease and shows mostly a very a favorable outcome after chemotherapy, treatment delay or dose reduction could potentially affect negatively the outcome. The aim of our review is to explore the current scientific literature on pegfilgratim use in HL, evaluating both observational than prospective trial. Moreover, analyzing the latter, we aim to define some practical suggestion about primary prophylaxis with pegfilgrastim in HL.
Abstract
Neutropenia and febrile neutropenia are common and potentially life-threating events associated with chemotherapy treatment in Hodgkin lymphoma (HL). Neutropenia-related infectious events could be an issue both for direct clinical consequences and for delay in treatment delivery, affecting final outcomes in a potentially highly curable disease. Pegfilgrastim is the pegylated form of filgrastim, the recombinant form of human G-CSF, capable of prevent and mitigate neutropenic effects of chemotherapy, when adopted as primary prophylaxis in several hematological malignancies. No updated version of major international guidelines provides clear indication on prophylaxis use of pegfilgrastim in HL to prevent febrile neutropenia episodes in HL. Moreover, to date, scarce and non-uniform clinical experiences evaluating pegfilgrastim as prophylaxis in HL are present in the literature. Herein, we propose a brief summary of the literature data about efficacy and safety of the use of pegfilgrastim as primary prophylaxis in HL during chemotherapy treatment.
Keywords:
pegfilgrastim; Hodgkin lymphoma; supportive care; G-CSF; primary prophylaxis
